TickerTalks
Browse all tickers →
TickerTalks›$ZTS
ZTZTS

Zoetis Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 2% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (170/wk), no spike
$ZTS·$32B·Drug Manufacturers - General·Healthcare
$74.53+0.6%YTD-41.0%1Y-51.2%
Mentions · last 7 days
2026-07-08: 20 posts2026-07-09: 20 posts2026-07-10: 25 posts2026-07-11: 8 posts2026-07-12: 28 posts2026-07-13: 40 posts2026-07-14: 29 posts170+14%
Price updated 10m ago·X counts updated 2d ago
ZTZTS
$ZTSZoetis Inc.
$74.53+0.62%170 posts+14%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ZTS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Zoetis down 51% in a year at 3% of 52w — Burry just went long on animal-health leader.

Zoetis is the largest global animal-health company — pet medications (Simparica Trio, Cytopoint) and livestock therapeutics. The stock is down 51% over the past year and sits at the 3rd percentile of its 52-week range, in the exact deep-value territory where Michael Burry disclosed a long position at $74.80.

  • Revenue grew 2% YoY last quarter with a 36% operating margin — modest growth but industry-leading operating margin; the multi-quarter deceleration reflects the post-pandemic pet-adoption normalization.
  • Trades at 13x TTM earnings, 3.5x sales, and a 6.4% FCF yield — genuinely reasonable multiples for a quality franchise with 32% ROIC; the -51% T12M drawdown captures the sentiment reset.
  • Michael Burry disclosed a long position at $74.80 (per corpus) — real smart-money accumulation at deep-value entry; the setup matches Burry's classic value-hunt pattern.
  • Multiple securities class-action lawsuits (Rosen, KTMC, Levi & Korsinsky notices) filed in July — opportunistic law-firm activity typical of a big drawdown; likely noise but worth flagging.
  • The July 15 Lenivia launch in Canada and EU is a real product-refresh catalyst; the July 14 director awards were routine equity grants.

August 6 Q2 earnings is the reset moment: revenue growth held plus specific FY27 pet-medication trajectory is what turns coiling into a base; a soft print or another quarter of deceleration is where -51% T12M extends further below $70. Real quality animal-health franchise at real deep-value entry — the Burry position captures the setup; the fundamental case rewards continued Lenivia launch execution and a stabilizing pet-medication demand backdrop.

Agrees with X sentimentThe bullish X take on Michael Burry's long position at $74.80, the Rep. Cisneros healthcare-heavy portfolio inclusion, and the $47-76 buy zone is analytically fair. The $405 target is aggressive but the direction is right; Burry's position is a genuine smart-money signal.

What to watch: Aug 6 Q2 earnings — need revenue growth held and specific FY27 pet-medication trajectory. A soft print or another quarter of deceleration is where -51% T12M extends further below $70.

On the calendar: 2026-08-06 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment⚠8 posts analyzed · as of 2026-07-13 · top-engagement diverged

Michael Burry disclosed a long position in Zoetis added at $74.80, and Rep. Cisneros disclosed a healthcare-heavy portfolio including ZTS, LLY, HQY, COO, and BIIB. Traders describe the stock down roughly 40% year-to-date and 52% over the last 12 months as an attractive long-term buy zone from $47 to $76 targeting $405, though at least one investor tracked its inclusion in fund-manager sell lists.

Read the AI verdict + X sentiment for $ZTS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

World's largest animal health company, selling vaccines, medicines, and diagnostics to livestock farmers and companion animal veterinarians in 100+ countries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $ZTS.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $ZTS

Neutral — World's largest animal health company, selling vaccines, medicines, and diagnostics to livestock farmers and companion animal veterinarians in 100+ countries; the oral GLP-1 and obesity pipeline expansion and competition does not materially affect this business's near-term earnings.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+16.4%YTD
+49.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
12.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
21.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
37.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
62.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
70.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$1.53$1.60-4.4%
Q4 2025Feb 12, 2026$1.48$1.40+5.7%
Q3 2025Nov 4, 2025$1.70$1.62+4.9%
Q2 2025Aug 5, 2025$1.76$1.62+8.6%
Next earningsThu, Aug 6·consensus EPS $1.85

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.3B+1.9%71.7%36.3%$1.42$291.0M
Q4 FY25$2.4B+3.0%68.9%34.6%$1.38$732.0M
Q3 FY25$2.4B+0.5%70.2%39.0%$1.63$805.0M
Q2 FY25$2.5B+4.2%72.3%40.2%$1.61$308.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$9.7B$9.7B – $9.9B$6.89$6.80 – $7.0314
FY27$10.1B$10.0B – $10.5B$7.37$7.07 – $7.7314
FY28$10.6B$10.6B – $10.6B$7.98$7.29 – $9.1214
FY29$11.2B$11.0B – $11.5B$8.74$8.59 – $9.069
FY30$11.6B$11.5B – $12.0B$9.38$9.22 – $9.7313

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-6.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-34.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 13Frank A DamelioDirector6.7K sh$501KBuyMay 13Paul BisaroDirector2.0K sh$152KBuyMay 11Michael B MccallisterDirector3.0K sh$233K
+ 51 other (27 awards · 12 exempts · 6 inkinds · 4 others · 2 gifts) in window

See when $ZTS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3/ANew insider — initial holdingsJul 143/A
AI summary

Zoetis (ZTS) filed a Form 3/A (amendment to Form 3) on July 14, 2026, correcting or supplementing an initial Section 16 ownership report for an officer or director. The excerpt does not detail the specific amendment content or the reporting person's name. Form 3/A amendments typically correct errors in the original filing or add omitted securities. No material new ownership information was discernible from the excerpt.

3New insider — initial holdingsJun 173
AI summary

Abhay U. Nayak filed an initial Form 3 for Zoetis Inc. upon re-becoming a Section 16 officer (EVP) effective June 15, 2026; the filing also corrects unreported transactions between October 11, 2022 and June 15, 2026, disclosing RSUs for approximately 5,904 common shares, stock options at exercise prices from $129.13 to $196.14, and phantom stock units. Corrective initial ownership disclosure covering a 3.5-year reporting gap; no new equity was awarded — only previously unreported existing grants are now captured.

8-KOfficer or director changeMay 228-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Zoetis Inc. (ZTS) filed an 8-K on May 20, 2026 disclosing a personnel change (Item 5.02) and annual shareholder meeting vote results (Item 5.07). Zoetis is a Parsippany, New Jersey-based animal health company listed on the NYSE. The excerpt does not identify the executive involved; annual meeting results are routine, but an officer change at a large-cap pharma company merits attention depending on the role.

8-KPress release / Reg FDMay 208-K — Item 7.01: Press release / Reg FD
AI summary

Zoetis Inc. (ZTS) filed an 8-K on May 20, 2026 under Item 7.01 (Regulation FD Disclosure). Zoetis is a Parsippany, New Jersey-based animal health company listed on the NYSE. Reg FD disclosures typically accompany investor presentations; for a large-cap animal health company, such disclosures may contain product pipeline updates or market guidance.

8-KPress release / Reg FDFeb 58-K — Item 7.01: Press release / Reg FD
+ 12 other (3 13Gs · 2 earnings 8-Ks · 2 proxys · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ZOETIS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTSnewsfilecorp.com·17h agoZoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMCprnewswire.com·23h agoLevi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTSprnewswire.com·1d agoZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Unionbusinesswire.com·1d agoZoetis (ZTS) Stock Dips While Market Gains: Key Factszacks.com·2d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$GILD$OGN
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport